India, Oct. 9 -- The Centre has decided to cap trade margins at 30 per cent of maximum retail price for all non-scheduled anti-cancer drugs, covering branded and generic, domestic and imported, patented, and non-patented medicines, Government sources said on Thursday.

The move addresses excessive trade mark-ups and aims to improve affordability while ensuring continued availability of these life-saving medicines, the sources said.

The decision, which is expected to be implemented later this month, will bring down prices of 110 anti-cancer drugs, including 35 patented medicines.

"The primary aim of the trade margin rationalisation (TMR) is to prevent mis-selling malpractices. There is a tendency to sell drugs having a bigger margin, and...